智能手机应用程序通过主动交通促进身体活动的用户感知:卡塔尔世界杯8强波胆分析智慧城市主动手机干预(SCAMPI)研究中的归纳性定性内容分析%A Lindqvist,Anna- karin %A Rutberg,Stina %A Söderström,Emmie %A Ek,Anna %A Alexandrou,Christina %A Maddison,Ralph %A Löf,Marie %+吕勒堡理工大学健康科学系健康、医学与康复学部，瑞典吕勒堡，9787,46 0725390660，anna-karin.lindqvist@ltu.se %K行为改变%K智能手机干预%K身体活动%K用户感知%K主动交通%K移动应用%K归纳定性内容分析%K移动健康%K社会认知理论%K移动健康%D 2020 %7 5.8.2020 %9原论文% JMIR移动健康Uhealth %G英语%X背景:缺乏身体活动是全球公认的发病率的主要危险因素，特别是非传染性疾病的发病率。因此，增加身体活动是一项公共卫生重点。参与主动交通(AT)是提高每日PA水平的可行方法。流动保健干预措施能够向更大的人口推广辅助治疗。智能城市主动手机干预(SCAMPI)研究是一项随机对照试验，旨在评估通过智能手机应用程序提供的行为改变计划的能力，以激励参与者通过参与AT来提高他们的PA。目的:本定性研究旨在检验SCAMPI试验中使用的推广AT的应用程序(TRavelVU Plus应用程序)的接受度和用户体验。方法:共有17名斯德哥尔摩县居民(13名女性;年龄在25-61岁之间)，在2018年的SCAMPI随机对照试验中完成了为期3个月的基于应用程序的行为改变项目(通过TRavelVU Plus应用程序提供)，同意参加半结构化的电话访谈。 These participants were well representative of the whole intervention group (n=127) in terms of baseline characteristics such as age, sex, and area of residence. The interviews were audiorecorded, transcribed verbatim, and analyzed using an inductive qualitative content analysis. Results: The content analysis revealed 2 themes and 4 subcategories. The first theme, “main motivators: monitoring and messages,” highlighted that monitoring AT and being able to set weekly goals using the app were the primary motivators reported by study participants. The second theme, “acceptable but modifiable,” reflects that the app was well accepted and effectively encouraged many participants to use more AT. Nevertheless, there were functions in the app that require modification. For example, while the semiautomated travel tracking feature was appreciated, participants found it time-consuming and unreliable at times. Conclusions: This study contributes novel insight into adults’ experiences of using a mobile app to promote the use of AT. The results showed that the app was well accepted and that self-monitoring and goal setting were the main motivators to engage in more AT. The semiautomated tracking of AT was appreciated; however, it was also reported to be energy- and time-consuming when it failed to work. Thus, this feature should be improved going forward. Trial Registration: ClinicalTrials.gov NCT03086837; https://clinicaltrials.gov/ct2/show/NCT03086837 International Registered Report Identifier (IRRID): RR2-10.1186/s12889-018-5658-4 %M 32755889 %R 10.2196/19380 %U https://mhealth.www.mybigtv.com/2020/8/e19380 %U https://doi.org/10.2196/19380 %U http://www.ncbi.nlm.nih.gov/pubmed/32755889